Wave Life Sciences has shared details of its upcoming Phase II/III clinical trial testing suvodirsen in boys with DMD. Suvodirsen is an exon-skipping drug that targets exon 51 within the dystrophin gene. The study, named DYSTANCE 51, will start in July 2019 and enrol boys who are between 5 and 12 years of age. Participants will receive suvodirsen or placebo once a week for 48 weeks.
For further information, please read Wave’s press release.